Skip to main content
Erschienen in: BMC Cancer 1/2024

Open Access 01.12.2024 | Correction

Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study

verfasst von: Monica Niger, Federico Nichetti, Lorenzo Fornaro, Chiara Pircher, Federica Morano, Federica Palermo, Lorenza Rimassa, Tiziana Pressiani, Rossana Berardi, Andrea Casadei Gardini, Elisa Sperti, Lisa Salvatore, Davide Melisi, Francesca Bergamo, Salvatore Siena, Stefania Mosconi, Rafaella Longarini, Giuseppina Arcangeli, Salvatore Corallo, Laura Delliponti, Stefano Tamberi, Elena Fea, Giovanni Brandi, Ilario Giovanni Rapposelli, Massimiliano Salati, Paolo Baili, Rosalba Miceli, Silva Ljevar, Ilaria Cavallo, Elisa Sottotetti, Antonia Martinetti, Michele Droz Dit Busset, Carlo Sposito, Maria Di Bartolomeo, Filippo Pietrantonio, Filippo de Braud, Vincenzo Mazzaferro

Erschienen in: BMC Cancer | Ausgabe 1/2024

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The online version of the original article can be found at https://​doi.​org/​10.​1186/​s12885-024-12225-6.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Correction to: BMC Cancer 24, 436 (2024)
Following publication of the original article [1], the authors reported an error in the funding section of their article. The correct funding statement is:
The present study is an investigator-driven trial, carried out by participating clinicians, who have the intellectual ownership of the results. The study is sponsored by Gruppo Oncologico del Nord Ovest, Cooperative Group having its headquarters at Via G. Mameli, 3–16,122 Genoa (ITALY) and funded by GONO Foundation. Part of the funding is also provided by Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, through institutional funds and a nonconditional support of Fondazione Anna Villa e Felice Rusconi Onlus. This project is also in collaboration with Intesa Sanpaolo S.p.A. No funds can be provided to ethical committees and single participating centers. The study will be conducted according to the current regulations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN
Literatur
Metadaten
Titel
Correction to: A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY tract cancers (BTC) at high risk for recurrence: PURITY study
verfasst von
Monica Niger
Federico Nichetti
Lorenzo Fornaro
Chiara Pircher
Federica Morano
Federica Palermo
Lorenza Rimassa
Tiziana Pressiani
Rossana Berardi
Andrea Casadei Gardini
Elisa Sperti
Lisa Salvatore
Davide Melisi
Francesca Bergamo
Salvatore Siena
Stefania Mosconi
Rafaella Longarini
Giuseppina Arcangeli
Salvatore Corallo
Laura Delliponti
Stefano Tamberi
Elena Fea
Giovanni Brandi
Ilario Giovanni Rapposelli
Massimiliano Salati
Paolo Baili
Rosalba Miceli
Silva Ljevar
Ilaria Cavallo
Elisa Sottotetti
Antonia Martinetti
Michele Droz Dit Busset
Carlo Sposito
Maria Di Bartolomeo
Filippo Pietrantonio
Filippo de Braud
Vincenzo Mazzaferro
Publikationsdatum
01.12.2024
Verlag
BioMed Central
Erschienen in
BMC Cancer / Ausgabe 1/2024
Elektronische ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12328-0

Weitere Artikel der Ausgabe 1/2024

BMC Cancer 1/2024 Zur Ausgabe

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.